Riik: Bangladesh
keel: inglise
Allikas: DGDA (Directorate General of Drug Administration)
Bisoprolol Hemifumarate
Popular Pharmaceuticals Ltd.
Bisoprolol Hemifumarate
2.5 mg
Tablet
Bisoprolol Fumarate 2.5 mg & 5 mg Tablet Beta COR Manufactured by: _POPULAR PHARMACEUTICALS LTD._ 164, TONGI INDUSTRIAL AREA, GAZIPUR, BANGLADESH PRESENTATIONS _Betacor 2.5 Tablet:_ Each film coated tablet contains 2.5 mg Bisoprolol Fumarate USP. _Betacor 5 Tablet:_ Each film coated tablet contains 5 mg Bisoprolol Fumarate USP. PHARMACOLOGY _Pharmacodynamic properties: _ Bisoprolol is a potent highly beta 1 -selective-adrenoceptor blocking agent, lacking intrinsic stimulating and without relevant membrane stabilising activity. It only shows low affinity to the beta 2 -receptor of the smooth muscles of bronchi and vessels as well as to the beta 2 -receptors concerned with metabolic regulation. Therefore, Bisoprolol is generally not to be expected to influence the airway resistance and beta 2 -mediated metabolic effects. Its beta1-selectivity extends beyond the therapeutic dose range. _Pharmacokinetic properties:_ Bisoprolol is absorbed almost completely from the gastrointestinal tract. Together with the very small first pass effect in the liver, this results in a high bioavailability of approximately 90%. The bioavailability is not affected by food intake. Bisoprolol shows linear kinetics and the plasma concentrations are proportional to the administered dose over the dose range 5 to 20 mg. Peak plasma concentrations occur within 2-3 hours.The plasma protein binding of Bisoprolol is about 30%. The distribution volume is 3.5 l/kg. The total clearance is approximately 15 l/h. The plasma elimination half-life (10-12 hours) provides 24 hours efficacy following a once daily dosage. Bisoprolol is metabolised via oxidative pathways with no subsequent conjugation. All metabolites, being very polar, are renally eliminated. The major metabolites in human plasma and urine were found to be without pharmacological activity. In vitro data from studies in human liver microsomes show that Bisoprolol is primarily metabolised via CYP3A4 (~95%) with CYP2D6 having only a minor role. Bisoprolol is excreted from the body by two routes, Lugege kogu dokumenti